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Abstract 
A SYSTEMS BIOLOGY APPROACH FOR UNDERSTANDING 
INFLAMMATION IN THE GASTROINTESTINAL TRACT OF A CROHN’S 
PATIENT 
 
By Gigi Gabrielle Meyer, Master of Science 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
Virginia Commonwealth University, 2013 
Major Director:  Rebecca A. Segal 
Associate Professor, Department of Mathematics and Applied Mathematics 
 
ABSTRACT:  A system of ordinary differential equations is developed to model the effect of 
fatty acids on chronic intestinal inflammation that is typical of a Crohn’s patient.  Several murine 
studies have shown an anti-inflammatory response when specific polyunsaturated fatty acids are 
included regularly in the diet. It is believed that the fatty acids serve as a specific ligand that 
activates the Peroxisome Proliferator Activated Receptor (PPAR) which is located on multiple 
cell types that are active in the inflammatory response.  The binding of the PPAR results in a 
suppression of the inflammatory pathway.  Results of the model indicate a muted inflammatory 
response when fatty acids are added regularly to the diet in mild to moderate cases of Crohn’s.  
Results of mathematical analysis show a stable fixed point with decreased inflammatory markers 
and pathogen levels when fatty acids are added regularly to the diet.   
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Chapter 1:  Introduction and Motivation 
 
Inflammation is a complex, multi-time scale process.  It is the body’s natural reaction to foreign 
invading pathogens or injury, and results in the removal of harmful stimuli, damaged cells or 
irritants, thereby aiding in the process of healing.  This initial reaction is meant to protect the 
body.  However, when inflammatory signals fail to resolve inflammation can become self-
perpetuating and harmful to the body.  Acute inflammation is the initial response to injury or 
infection; there is a rapid onset and it can quickly become severe.  Chronic inflammation 
happens over an extended period of time, sometimes months or years.  Several scenarios may 
lead to the state of chronic inflammation.  The typical scenario is one in which there is a failure 
to eliminate the original stimulus that caused the acute inflammation.  A second possible course 
to chronic inflammation is through the onset of an autoimmune response in which immune cells 
attack healthy tissue, by mistaking them for foreign material.  A final possible trigger for chronic 
inflammation is the presence of a chronic and persisting irritant (Linder and Melby, 2012).  
Some diseases that are caused by chronic inflammation include asthma, tuberculosis, rheumatoid 
arthritis, chronic periodontitis, ulcerative colitis and Crohn’s disease, chronic sinusitis, and 
chronic active hepatitis.   
During acute inflammation three main processes occur:  First, arterioles (small branches of 
arteries that lead to capillaries) dilate, which results in increased blood flow.  Second, capillaries 
become more permeable, resulting in an increased rate of blood proteins and fluid moving into 
the interstitial spaces (between tissues).  Third, neutrophil and macrophage immune cells move 
in to the interstitial spaces (Linder and Melby, 2012). The possible outcomes of acute 
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inflammation are 1) a healthy resolution (and inflammation is removed), 2) an abscess develops 
(and infection may persist), or 3) chronic inflammation.   
The outcomes of chronic inflammation is the most severe of the “failed” outcomes, resulting in 
destruction of tissue, a thickening and scarring of connective tissue, and the possible death of 
cells and tissues.  Common treatments used to control inflammation include non-steroidal anti-
inflammatory drugs (NSAIDs), such as naproxen, ibuprofen and aspirin, are taken to alleviate 
pain caused by inflammation, and to counteract the cyclooxygenase (COX) enzyme which 
synthesizes prostaglandins that promote inflammation (Nordqvist, 2012).  Corticosteroids are a 
class of steroid hormones that are anti-inflammatory by preventing phospholipid release, which 
blocks mechanisms involved in inflammation.  Lastly, a newly developed medication is Immune 
Selective Anti-Inflammatory Derivatives (ImSAIDs), (Mathison et al., 2010).  This therapy is a 
class of peptides that alter the activation and migration of immune cells that are involved in 
amplifying the response.  Since these drugs do have side effects, the diet can be a useful tool to 
modify inflammation.  Some foods have been shown to have anti-inflammatory properties; in 
particular, Omega-6 fish oils and tart cherry juice have been shown to reduce inflammation when 
ingested regularly (Sleigh et al., 2012).  Anti-inflammatory diet modifications will be described 
in more detail in Chapter 2. 
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CHAPTER 2:  BIOLOGY BACKGROUND 
 
INFLAMMATORY BOWEL DISEASE (IBD) 
Inflammatory Bowel Disease (IBD) is characterized by chronic inflammation in response to 
bacteria in the lumen microflora, which results in lesions of the epithelial lining and lamina 
propria (Swidsinski et al., 2002).  There are two common types of IBD – Ulcerative Colitis and 
Crohn’s disease.  An estimated 1.4 million individuals suffer from IBD in the U.S. (Herrinton et 
al., 2007).   
In a healthy individual, immune cells of the gut are mostly inactive towards the populations of 
bacteria in the microflora.  This tolerance is attributed to the presence of regulatory immune cells 
that are antagonistic to the inflammatory pathways.  Inflammatory pathways triggered by small 
populations of pathogenic bacteria are quelled by the presence of these anti-inflammatory 
regulatory cells.  However, in IBD the immune system mistakes food, bacteria, and other 
materials for foreign invading substances and will attack cells of the intestine.  In a normal, 
healthy individual, invading bacteria are destroyed, and then regulatory cells stop the process.  In 
IBD, the inability of the regulatory cells to stop the inflammation response and/or the 
overwhelming response to materials mistakenly identified as foreign invading substances causes 
the indiscriminate release of toxic peroxide anions, proteases, and oxygen / nitrogen radicals by 
pro-inflammatory immune cells.  This leads to tissue damage.   
Based on the process as described above, modeling inflammation for Crohn’s disease is unique 
for two main reasons.  First, in a sterile organ system, the immune processes are generally 
stopped when the pathogen population has been eliminated.  However, in the intestine, antigens 
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that induce inflammation (bacterial microflora, food) cannot be entirely eliminated, and so if left 
unchecked, the collateral damage of the immunopathogenesis can become more harmful to the 
host than the invading bacteria (Wendelsdorf et al., 2010).  Second, as intestinal tissues are 
damaged in this process, the epithelial barrier between the lumen and lamina propria allows 
bacteria to cross into the lamina propria, thereby inducing an additional positive feedback loop 
that magnifies the inflammation.  Figure 1 (Rubin and Farber, 1995) shows a section of the 
intestine in Crohn’s disease.  The lamina propria is inflamed and swollen.  There are also lesions 
in which bacteria from the lumen may leak in to the lamina propria, which further exacerbates 
the inflammation response. 
Figure 1:  The intestine in Crohn’s disease (Rubin and Farber, 1995). 
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Crohn’s disease can involve any section of the gastrointestinal tract, but occurs most frequent at 
the end of the small intestine or at the beginning of the large intestine.  Crohn’s may affect all 
layers of the gastrointestinal tissue, and symptoms include persistent diarrhea, cramping 
abdominal pain, fever, rectal bleeding, and fatigue.  A common complication is blockage of the 
intestine due to swelling and scar tissue, and sometimes ulcers within the intestinal tract that may 
become infected fistulas (Sohrabpour et al., 2010).  As a result of these complications, an 
individual may be depleted of proteins, calories, and vitamins.  Ulcerative colitis is limited to the 
large intestine, and only affects the top layers of the intestine.  Up to 80% of patients with 
Crohn’s eventually require surgery to remove sections of the intestine, which may not entirely 
cure the individual (Cosnes et al., 2011).  In contrast, for Ulcerative colitis patients that are 
unresponsive to medication and require surgery to remove portions of the colon, the condition 
does not reoccur. 
 
THE INFLAMMATION PATHWAY 
The inflammation response specific to the intestinal tract involves many immune defense cells 
and pro- and anti-inflammatory chemical mediators that help to regulate the system from the 
onset to conclusion of an infection.  Mast cells are typically the first responders to an invading 
pathogen, and also carry out some inflammatory-mediating functions.  Mast cells are found in 
the connective tissue and mucous membranes of the body, and contain mediator granules of 
histamine, eosinophil chemotactic factor, neutrophil chemotactic factor, platelet activating factor, 
and cytokines IL-3, IL-4, IL-5, IL-6 and TNF-alpha (Kaiser, 2011).  They are also capable of 
processing leukotriene and prostaglandins which act as pro-inflammatory mediators.  See Table 
1 for a description of each of these chemical mediators (Kaiser, 2011; Tilg et al., 2013). 
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Table 1:  Inflammatory mediators released by the Mast Cell 
Histamine 
Pro-
Inflammatory 
Constriction of smooth muscles, vasodilation, 
increased mucous secretion. 
 
Eosinophil 
chemotactic factor 
Pro-
Inflammatory 
Recruits Eosinophils 
 
Neutrophil 
chemotactic factor 
Pro-
Inflammatory 
Recruits Neutrophils 
 
Platelet activating 
factor (PAF) 
Pro-
Inflammatory 
Activator and mediator of leucocyte functions – 
platelet aggregation, inflammation, and anaphylaxis. 
TNF-  
Pro-
Inflammatory  
Recruits Neutrophils 
IL-1 
Pro-
Inflammatory 
Recruits Phagocytes, Lymphocytes 
IL-3 
Pro-
Inflammatory 
Recruits Monocytes and Dendritic Cells 
IL-5 
Pro-
Inflammatory 
Stimulates B cell growth, immunoglobulin secretion, 
eosinophil activation 
Leukotrienes 
Pro-
Inflammatory 
Cause prolonged constriction of smooth muscles. 
Prostaglandins 
Pro-
Inflammatory 
Increased vascular permeability constricts smooth 
muscles, magnify pain and induce fever. 
IL-4 
Anti-
Inflammatory 
Suppress IL-1 and TNF 
IL-6 
Anti-
Inflammatory 
Neutralizes effects of IL-1, induce release of IL-1 and 
TNF antagonists 
 
Mast cells have pattern-recognition receptors (PRRs) on the surface of the cell that interact with 
pathogen-associated molecular patterns (PAMPs.)  The PAMP of an invading pathogen will bind 
to a PRR, and mast cells will release granule contents.  This promotes inflammation, and attracts 
other immune defense cells to the site of infection. 
The next cells to react are dendritic cells, and are derived from monocytes in an immature form.  
Once the dendritic cell has engulfed antigens and is activated by pro-inflammatory cytokines, the 
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dendritic cell will migrate to regional lymph nodes.  At this point, the dendritic cell will present 
antigens to the populations of naïve T-lymphocyte cells.  Dendritic cells engulf microorganisms 
and other foreign materials and degrade the material with lysosomes; peptides from microbial 
proteins are then bound to a MHC-II molecule and put on the surface of the cell, where they are 
recognized by T-cell receptors and CD4 molecules on naïve T4-lymphocytes and T8-
lymphocytes.  These T-cells then become activated, proliferate, and differentiate into effector 
cells.  Dendritic cells also produce pro-inflammatory cytokines.  Monocytes respond to anti-
inflammatory and pro-inflammatory cytokine signals (Mosser, 2003).  
Monocytes reside in the blood, and when signaled, migrate from the blood and enter the tissue to 
become activated and differentiate into macrophages.  The defense functions of macrophages are 
to kill microbes, infected cells, and tumor cells by phagocytosis.  Once macrophages engulf 
microorganisms, they can become activated by T-helper lymphocytes, and produce an increased 
number of lysosomes.  Like dendritic cells, peptides from engulfed and degraded 
microorganisms are bound to the MHC-II molecule and put on the cell surface of the 
macrophage to be recognized by T-cell receptors and CD4 molecules on effector T4-
lymphocytes.  This leads to the activation and differentiation of the macrophage.  Type I 
macrophages are pro-inflammatory and function to release toxins that destroy surrounding 
pathogens; type II macrophages are anti-inflammatory and function to help heal the body.  
Cytokines TNF- , IL-1, IL-6, and IL-8 are produced by macrophages; these chemicals induce 
fever, increase phagocytosis and energy output, promote sleep, activate resting T-lymphocytes, 
attract and activate neutrophils, and stimulate endothelial cells to replicate, form capillaries and 
fibroblasts that form connective scar tissue.  Figure 2 (Hogan Lab, 2009) provides a spatial 
description of immune defense cells in the intestine; the figure displays the reactions of an 
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individual with a food allergy, comparable to that of a hypersensitive immune response in an 
individual with Crohn’s. 
 
Figure 2:  Intestinal Immune Response from a food allergy (Hogan Lab, 2009). 
 
 
THE PPAR RECEPTOR 
It is believed that fatty acids serve as a specific ligand that activates the Peroxisome Proliferator 
Activated Receptor (PPAR), and that the binding of the PPAR results in a suppression of the 
inflammatory pathway. PPAR is a member of the nuclear receptor family of transcription factors.  
Nuclear receptors are a class of proteins found within cells that sense steroid and thyroid 
hormones and once bound by a specific signaler, have the ability to regulate gene expression.  
Nuclear receptors have the ability to directly bind to DNA and regulate the expression of 
adjacent genes.  This regulation of gene expression by the nuclear receptors is generally only 
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possible when a specific ligand (a molecule that can affect receptor behavior) is present.  The 
ligand, once bound to the nuclear receptor, will result in a conformational change of the receptor, 
which will cause activation and resulting up or down regulation of gene expression.  For 
example, polyunsaturated fatty acids (PUFA) serves as a ligand to the PPAR receptor, and down-
regulates with an anti-inflammatory effect.  Omega-6 fatty acids are a type of PUFA, found in 
flaxseeds, walnuts, fish, and oils.   
Studies have found a high concentration of the PPAR receptor in the upper gastrointestinal tract, 
and through the layers of luminal tissue.  Due to the location and the prevalence of Crohn’s 
disease in this region, and the regulatory activities described earlier in this section, PPAR 
receptor may play a fairly involved role in the disease.  In one particular study, the abundance, 
distribution, and function of PPAR- were analyzed in murine epithelial cells taken from the 
small and large intestine (Su et al., 2007).  The study found that receptor subtype PPAR- was 
located throughout the colon, with significantly more found in the proximal 1/3 of colon – or 
upper small intestine – and most intensely in luminal cells of the proximal colon.  Lesser 
amounts of the receptor were found in the subluminal cells, which indicates that PPAR- is 
expressed in all cells of intestinal proximal crypts.   
 
THE DIET 
As mentioned earlier, many medications are available to treat chronic intestinal inflammation, 
but the side effects can be serious (increased intestinal irritation and inflammation, rashes and 
darkening of the skin, upset stomach, vomiting, diarrhea, muscle aches, abdominal pain, flu-like 
symptoms, headache, anxiety, insomnia – CCFA, 2010).  Therefore, modifications to the diet 
may serve as an important tool in controlling the inflammatory response.  Along with normal gut 
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microbiota, dietary foods are the most common luminal antigens in the bowel and may influence 
intestinal inflammation (Cabre and Domenech, 2012).  Possible mechanisms by which dietary 
products have an influence are by having a direct antigenic effect, by alteration of gene 
expression, and by modulation of inflammatory mediators.  High intakes of total fat, omega-3 
fatty acids, and meat were associated with higher risk for developing IBD, while high vegetable 
and fruit intake were associated with a  decreased risk (Hou et al., 2011)  Diets high in refined 
sugars also were implicated in the development of Crohn’s and Ulcerative Colitis (Hansen et al., 
2011).  A low-residue diet (i.e., devoid of insoluble fiber) is advised during flares of IBD.   
As mentioned earlier, PUFA may play some anti-inflammatory role as a ligand to the PPAR 
receptor.  Several studies have been conducted to measure the activity of the PPAR receptor in 
response to various types of PUFA.  Conjugated Linoleic Acid (CLA), naturally found in milk, 
cheese, and other dairy products, has been found to suppress colonic inflammation and up-
regulated PPAR-gamma (Bassaganya-Riera and Hontecillas, 2010.)  Another study found similar 
effects with Punicic acid (Bassaganya-Riera et al., 2011).  Table 2 gives a summary list of pro- 
and anti-inflammatory diet modifications (Drake, 2007). 
 
Table 2:  Diet modifications 
Pro-Inflammatory Anti-Inflammatory 
Trans Fatty Acids Omega-6 Fatty Acids 
Saturated Fatty Acids Low Cholesterol Diets 
High Glycemic Index Foods Low Glycemic Index Foods 
Excessive Alcohol Dietary Fiber 
Smoking Arginine-rich foods (fish, nuts) 
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CHAPTER 3:  MATHEMATICAL BACKGROUND 
 
Due to its complex nature, the inflammatory response has attracted the interest of mathematical 
biologists, and several models of inflammation have been proposed.  A reduced mathematical 
model of the inflammatory response that incorporates pro-inflammatory and anti-inflammatory 
elements has been shown to simulate a patient’s “health” and “death” scenarios following acute 
inflammation (Reynolds et al., 2006).   Figure 3 (Reynolds et al., 2006) represents the 
interactions provided in the reduced four-variable model.  Arrows and bars represent up- and 
inhibition, or down-regulation in the inflammatory cascade.  The balance of pro-inflammatory 
and anti-inflammatory processes and the overall effect on an infection and pathogen population 
is well suited for a dynamic model.   
Figure 3:  Interactions included in the four-variable model of acute inflammation 
(Reynolds et al., 2006). 
 
 
 
 
 
 
 
In this model, components of the adaptive immune response, such as T cells and specific 
antibodies are not included.  The reduced model consists of four differential equations, with 
dependent variables representing the levels of pathogen (P), activated phagocytes (N*) – such as 
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activated neutrophils, tissue damage (D) and anti-inflammatory mediators (
AC ), such as cortisol 
and interleukin-10.  A two-variable subsystem N* / P and N* / D are analyzed, using 
AC as a 
parameter, and then these subsystems are combined to form a three-variable model.  Finally, the 
AC  dynamics is incorporated into the system to create the four-variable model.  The subsystem 
approach was used to ensure consistency with biological processes, and evaluated through 
simulations and bifurcation analysis.   
Fixed points, also known as a critical points or equilibrium points, are calculated by setting the 
derivatives of each variable in the system to zero.  Fixed points were calculated in Reynolds et 
al. (2006) subsystems to determine parameter ranges in which stability and bifurcations occurred.  
A bifurcation occurs in system behavior when a change in parameter value alters the number of 
fixed points or their stability.  Reynolds et al. (2006) model finds three equilibrium points, 
corresponding to health state, aseptic, and septic death.
  
Reynolds et al. (2006) four variable model is useful because it is easier to analyze in context of 
immune pathology than a much larger system of differential equations, but the non-specific 
nature of the model may lose some of the actual biological processes involved.  In contrast, a 
system of twenty-nine ordinary differential equations was proposed to model the 
immunopathology of Inflammatory Bowel Disease (Wendelsdorf et al., 2010).  In this case, 
simulations were able to reveal a positive feedback loop between the inflammatory type-I 
macrophage and the anti-inflammatory type-II macrophage.  The ability of the type-I 
macrophage to be removed from the site of infection, either by reverting back to an 
undifferentiated state, or to a type-I macrophage, helped to cease immunopathogenesis even as 
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bacteria continue to reside at the site of infection and are eliminated by other immune defense 
cells.  Wendelsdorf et al. use three location compartments in their model – lumen (inner 
intestine), lamina propria (first underlying layer, or effector site), and mesenteric lymph node 
(deepest layer in intestinal wall, or inductive site.)  Populations are tracked depending on 
whether they are in an effector or inductive site.  By including these separate compartments, this 
model provides a useful method to track inflammation in each anatomical layer of the intestine. 
Although the 29-ODE system proposed by Wendelsdorf et al. extensively covers the range of 
immune cells involved in the anatomical compartments specific to Crohn’s, the number of ODEs 
involved makes the set of equations hard to work with.  The study does not identify any steady 
state, or conduct bifurcation analysis.  Also, Wendelsdorf et al. mentions the PPAR-gamma 
receptor as a possible cause of the macrophage-switch activity but does not provide any direction 
for how to modify the Effector / Inductive macrophage equations to isolate or simulate this 
activity, as with the addition of PUFA.  
 
Another modeling approach has been to detail the biological interactions that may cause 
progression from an acute to chronic state.  Herald (2009) presents a system of four nonlinear 
ordinary differential equations specific to the dynamics of respiratory infections that initiate 
inflammation of the airway and lead to such conditions as cystic fibrosis and chronic obstructive 
pulmonary disease.  This four-variable system describes the interactions of macrophages, 
populations of pro-inflammatory and anti-inflammatory cytokines, and bacteria (pathogens).   
The focus of the model is to characterize the dynamics of chronic inflammation in the absence of 
pathogens.  Specifically, to model (1) inclusion of anti-inflammatory cytokines to suppress 
chronic inflammation, (2) model whether the presence of non-aggressive bacteria can cause 
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chronic inflammation after an infection has been resolved, and (3) model the effectiveness of 
cytokine therapies on chronic inflammation.  Figure 4 below shows the interactions of the four 
variables included in the Herald model.  The model was able to simulate healthy behavior as well 
as chronic inflammation in the presence or absence of bacteria.  After the introduction of 
bacteria, the model showed five possible outcomes:  (1) uncontrolled bacterial growth, (2) 
clearance of bacteria with resolution of inflammation, (3) clearance of bacteria with chronic 
inflammation, (4) chronic bacterial infection with inflammation, and (5) oscillations in the 
bacterial population with inflammation.   
Figure 4:  Interaction of variables in the chronic inflammation model, (Herald, 2010.) 
 
In comparison, both Herald and Wendelsdorf et al. track both pro- and anti-inflammatory 
cytokine populations, while Reynolds tracks an anti-inflammatory cytokine population and a 
general pro-inflammatory pathogenesis response.  It could be that tracking the anti-inflammatory 
cytokine population is of more importance to studying the macrophage dynamics of the model 
than pro-inflammatory cytokines alone.  The results of both Wendelsdorf, et al.’s and Herald’s 
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models focus on this cytokine-macrophage dynamic; while Reynolds et al, 2006 has grouped a 
non-specific local immune response (mast cells, monocytes, undifferentiated macrophages, 
neutrophils) into a non-specific group that is taken to be at Quasi steady state and focused on the 
pathogen / phagocytic immune cell population, given by N* and treated as a combined 
neutrophil / type I macrophage combo.  The general connecting theme of these models thus far 
has been to model the underlying dynamics of cytokine targets.  However, it may be useful to 
also model possible inhibitors of pro-inflammatory cytokine production, such as the PPAR 
receptor in combination with the cytokines. 
Herald presents the populations of macrophage, pro- and anti-inflammatory cytokines and 
pathogen present in alveoli in the equations shown below.  A new model of inflammation with 
fatty acid diet modifications was developed from these equations, and is presented in the next 
chapter.   
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The pathogen population here is a generic stimulus that may trigger chronic inflammation, which 
can include pathogenic or non-pathogenic bacteria, viruses and pollutants.  The pathogen growth 
rate here is exponential.  Even in the absence of bacteria, the macrophage population is 
maintained through the source term, s.  Once a pathogen has entered the respiratory tissue, the 
macrophage population will recruit more cells through pro-inflammatory cytokines that are 
signaled to fight the infection (Herald, 2009.)  The population of pro-inflammatory cytokines 
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increases through pathogen-induced production and the positive feedback from the pro-
inflammatory cytokine / macrophage loop.  
Herald’s 4-variable system above was chosen to be modified to a new 5-variable model of pro- 
and anti-inflammatory processes.  It provides a good starting point for because many specific 
terms are included, yet the simplicity of the model allows for mathematical analysis.  An 
additional macrophage term can be added to the system to represent Alternative-type 
macrophages, and the macrophage and cytokine equations can be modified to include the anti-
inflammatory effects of fatty acids.  The model is explained in further detail in Chapter 4:  Model 
Development. 
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CHAPTER 4:  MODEL DEVELOPMENT 
 
The model presented in this paper includes five ordinary differential equations that are specific to 
inflammation occurring in the lamina propria of a Crohn’s patient.  The presented system aims to 
describe the anti-inflammatory effects of alternate-type macrophages and dietary fatty acids as a 
possible treatment to inflammation in Crohn’s.  Table 3 below shows variable definitions for the 
model. 
Table 3:  Variable Definitions for the Chronic Inflammation Model 
Variable Units Definition 
M1 Cells Lamina Propria type-1 macrophage population 
MA Cells Lamina Propria type-II and type-III macrophage population 
CP Pg/ml Pro-inflammatory cytokine concentration 
CA Pg/ml Anti-inflammatory cytokine concentration 
P Cells Bacterial / antigen population 
 
Figure 5 is a diagram of the inflammatory and anti-inflammatory pathways in the model. 
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Pathogen (P) 
Initiating Event 
Inflammation 
Alternate 
Macrophages 
(MA) 
Anti-Inflammatory 
Cytokines (CA) 
Fatty Acid 
Figure 5:  Inflammation Pathways of the 5-variable model. Arrow represent upregulation, 
bars represent inhibition. 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
MAST CELLS 
 
Mast cells are unique in that they store preformed inflammatory mediators in their granules, 
poised for immediate release on activation. Like other immune cells, mast cells can also provide 
sustained synthesis and release of these products. Granules can also be re-generated for later 
cycles of degranulation from the same mast cell.  Therefore, mast cells are deemed to be 
considerable contributors in this model.   
type-I 
Macrophage 
(M1) 
Pro-Inflammatory 
Cytokines (CP) Damage 
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The mast cell has powerful pro- and anti-inflammatory effects.  Granules contain a variety of 
bioactive proteins that cause inflammation:  neutrophil chemoattractants leukotriene B4, 
interleukin 8 (kerotinocyte-derived chemokine in rodents), macrophage inflammatory protein-2, 
and tumor necrosis factor (TNF) are all prestored and can be released within seconds of cell 
activation. In addition, histamine and serotonin will induce vascular permeability, which allows 
influx of fluid, immune cells, and proteins to the damaged tissue.  Anti-inflammatory cytokines 
generated by mast cells include:  IL-4, which drives the T-helper Lymphocyte type 2 (Th2) 
responses, which releases additional anti-inflammatory cytokines (Kaiser, 2011; Tilg et al., 
2013). 
The equation (1) below indicates that mast cells release both pro- and anti- inflammatory 
cytokines in the presence of pathogens.  Mast cells are then considered to have released their 
store of granules are removed from the system.  Here, pro-inflammatory cytokines are created at 
rate 
pk  and anti-inflammatory cytokines created at rate ck .   
 
* smtP MT P
MT P CA CP P
  
   
 
* * * * *
dMT
smt P kp MT P kc MT P
dt
    (1) 
The mast cell activity happens very quickly compared to the other system dynamics and so is 
then taken to be at quasi-steady state: 
0 * * * * *
* * *( )
( )
p c
p c
p c
smt P k MT P k MT P
smt P MT P k k
smt
MT
k k
  
 


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This term is further simplified to a macrophage source term similar to that presented in the model 
by Herald (2009). 
PRO-INFLAMMATORY CYTOKINES AND TYPE-I MACROPHAGES 
The cytokines released by mast cells signal undifferentiated macrophages (monocytes) to 
migrate to the site and differentiate into type-I and alternate-type macrophages.  First, pro-
inflammatory cytokines represented by CP will signal a differentiation to the type I form with 
rate a.  This is represented by a source term ( 1s ) in the M1 equation below, and considered to be 
constant within the model area of the lamina propria.  Dietary fatty acid is thought to have a 
suppressive effect on the differentiation of type-I macrophages and instead encourages alternate-
type differentiation.  Because of this, it is included in and represented by the anti-inflammatory 
cytokine population.  Both types of macrophages are modeled with the same cell death rate 1M .   
 
1
1
1
1
1 *
* 1
1
1 *M
s
r
k CP
M
CP CP M
M



 

 
1
1
1
*1
1 * 1
1 *
M
r CPdM
s M
dt k CP
  

  (2) 
 
Even in the absence of cytokines, because of the positive 1s  source term, the macrophages have 
a positive, non-zero steady state of 1*1 1 Ms M , or
1
1
1
M
s
M

 .  Biologically, this represents the 
background level of immune cells that are always present and ready to react to any invading 
pathogen.   
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Similar to the system modeled by Herald, 
1r  represents the recruitment rate for type-1 
macrophages in response to pro-inflammatory cytokine.   1k  is the saturation constant for pro-
inflammatory cytokine-induced macrophage recruitment. The recruitment rate for a type-I 
macrophage response is stronger than the alternate-type macrophage response.  The saturation 
constant 1k  determines how quickly the 
1
1
*
1 *
r CP
k CP
 term will grow.  For example, a smaller 
value will generate faster macrophage recruitment. 
Pro-inflammatory cytokines are first generated by type-1 macrophages when they come into 
contact with pathogens or antigens.  They are also generated in the absence of pathogens or 
antigens through a positive-feedback loop with type-1 macrophages.  Dietary fatty acids and 
anti-inflammatory cytokines are theorized to slow the release of pro-inflammatory cytokines by 
binding to the PPAR receptor of the type-I macrophage and inhibiting pro-inflammatory 
cytokine release.  Cytokines have a relatively short half-life, C .   
 
*
11
11
)1)(1(
*
32

 


C
cp
CP
CPMM
MPCPMP
CAkCPk
CPa
p

 
 
The rate equation for pro-inflammatory cytokines is thus: 
2 3 4
*
* * 1 1*
(1 )(1 )(1 )
CP C
dCP a CP
p P M M CP
dt k CP k CA k FA
  
  
 (3) 
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DIETARY FATTY ACIDS 
As discussed earlier, dietary fatty acids such as Butyrate, Conjugated Linoleic Acid and Punicic 
are theorized to have a beneficial effect in the health of Crohn’s patient by suppressing 
inflammation caused by pathogens or dietary antigens.  For the purpose of the model, it is 
theorized that fatty acid intake will have a direct anti-inflammatory effect.  This is thought to 
occur though the actions of the PPAR receptor, blocking further recruitment of pro-inflammatory 
cells and cytokines (Mosser, 2002).  Fatty acids are therefore added directly into the anti-
inflammatory cytokine levels.  This group inhibits pro-inflammatory cytokine release by type-1 
macrophages and promotes differentiation to alternate-type macrophages.  Parameter 4k  
represents the fatty acid absorption rate of the fatty acid intake .FA  
ANTI-INFLAMMATORY CYTOKINES AND ALTERNATE-TYPE MACROPHAGES 
Anti-inflammatory cytokines are released when alternate-type macrophages come into contact 
with pro-inflammatory cytokines.  For the anti-inflammatory cytokines CA we have: 
*
ca
C
p
CP MA CP MA CA
CA

   

 
 
The rate equation for pro-inflammatory cytokines is thus: 
* *CA C
dCA
p CP MA CA
dt
    (4) 
 
Next, the anti-inflammatory effects of type-II and type-III macrophages are combined into an 
“alternate” category.  Fatty Acids are theorized to help recruit alternate-type macrophages by 
binding to PPAR receptors: 
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2 3
1
1 4
( * * )
2 *
(1 * )(1 * )
M
r CA r FAdMA
s MA
dt k CA k FA


  
 
  (5) 
PATHOGENS 
The pathogen equation was modified from the one presented in the Herald (2009) paper.  As 
discussed earlier, the intestinal lumen is host to a multitude of naturally occurring bacteria.  Any 
bacteria that move past the epithelial barrier into the lamina propria become pathogen invaders.  
In Crohn’s disease, the inflammatory response is often out of balance with the actual pathogen 
invasion that as occurred.  Type-1 macrophages emit toxic peroxide anions, proteases, and 
oxygen / nitrogen radicals (NO) that cause damage to tissues surrounding it.  A tissue-damage 
term was developed in Reynolds et al. (2006), model paper, and is included in the model here.  In 
this system, damage that occurs to the epithelial tissues breaks the barrier between the intestinal 
lumen and the Lamina Propria.  Since this lack of barrier allows many of the naturally-occurring 
bacteria to slip into the Lamina Propria site, the damage term has a positive effect on the growth 
of the pathogen.  This has been added to the pathogen equation with fd (damage function.)  
Pathogens enter through breaks in the epithelial barrier at this rate.  For the purposes of fixed 
point analysis, this term was treated as a constant rate, dam .  This implies that damage will 
continue to occur, and provide a positive input for pathogens, no matter how small the 
population of type-I macrophages.  However, in simulations, a function was used to emulate a 
non-zero background level of immune cells which does not cause damage.  Damage will occur 
 24 
 
only when type-I macrophage levels and resulting NO levels are high enough.  Thus, the 
presence of type-I macrophages will not incur any damage at some normal threshold.  The 
function used in simulations models damage as zero below this threshold.  The anti-
inflammatory cytokines and alternate-type macrophages help to repair tissue damage and subdue 
the inflammation.  Therefore, a greater percentage of the anti-inflammatory cells in the system 
will decrease the damage that occurs.  When pro-inflammatory type-1 macrophages make up a 
greater percentage of the system, damage to the tissues will occur.  The damage function is 
shown below, where percentage c represents the balance necessary between type-1 macrophages, 
alternate-type macrophages and fatty acid in the system for damage to occur.  If type-1 
macrophages surpass this percentage difference, then damage occurs at a rate proportional to the 
population of type-1 macrophages in the system.  Otherwise, no damage occurs.   
( 1 * 0)fd if M c MA    then  ( * 1)dam M  (0)else  
 
The pathogen equation is presented below in the form used for fixed point analysis: 
* * 1 *( 1 * )p
dP
kpg P e M dam M c MA
dt
      (6) 
 
Table 4 shows parameter definitions for the 5-variable model. 
Table 4:  Parameter Definitions for the Chronic Inflammation Model 
Parameter Units Definition 
Parameter 
Value 
1, 2s s  cells / hour 
Source term for the lamina propria 
macrophage population 
0.0125 - 0.08 
(Reynolds) 
1r  
Cells / 
((pg/ml)*hour) 
Recruitment rate for type-1 macrophages 
in response to pro-inflammatory cytokine 
0.01 (Reynolds) 
2r  
Cells / 
((pg/ml)*hour) 
Recruitment rate for alternate-type 
macrophages in response to anti-
inflammatory cytokine 
0.008 (estimated) 
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3r  
Cells / 
((pg/ml)*hour) 
Dietary intake / absorption rate for fatty 
acids 
0.0001 – 0.0005 
(estimated) 
M  1 / hour 
Natural rate macrophages leave due to 
death or migration 
0.002 (Reynolds) 
 
a 
 
Cells / hour 
 
Auto-induction rate of pro-inflammatory 
cytokine production 
 
0.002 (estimated) 
cpp  
(pg/ml) / (cells^2 
* hour) 
Bacterial induced inflammatory cytokine 
production rate 
0.01 (estimated) 
cap  
(pg/ml) / (cells^2 
* hour) 
Production of anti-inflammatory cytokine 0.04 (Reynolds) 
C  1 / hour 
Half-life of cytokines 
 
0.02 (estimated) 
1k  1 / (pg/ml) 
Saturation constant for pro-inflammatory 
cytokine induced macrophage recruitment 
0.7 – 0.9 
(estimated) 
2k  1 / (pg/ml) 
Saturation constant for production of pro-
inflammatory cytokine through auto 
induction 
0.7 – 0.9 
(estimated) 
3k  1 / (pg/ml) 
Saturation constant for inhibition of anti-
inflammatory cytokines 
0.7 – 0.9 
(estimated) 
4k  1 / (pg/ml) Saturation constant for fatty acid binding 
0.5 – 0.8 
(estimated) 
kpg 1 / hour Bacterial growth rate 
0.021 – 2.44 
(Reynolds) 
pe  1 / (cells * hour) Bacterial death rate due to macrophages 0.6 (Reynolds) 
c  Threshold at which damage occurs. 
0.8 – 1.2 
(estimated) 
FA (pg/ml) Dietary Fatty Acid Intake 0 – 2 (estimated) 
Dam M1-c*MA Damage produced by type-I macrophages 
0.35 – 0.5 
(estimated) 
 
The parameters in the table above were estimated or drawn from values given in the Reynolds et 
al. (2006) inflammation model.  
In order to identify the sensitive parameters in the model which lead to chronic inflammation, the 
system was non-dimensionalized.  This allows the relative sizes of the variables and parameters 
of the model to be better understood.  The non-dimensionalized system is shown below, and the 
new parameters are shown in Table 5.  Non-dimensionalized variables are given by ( m1, ma, cp, 
ca, p ).   Herald’s (2009) original scaled values were used in these equations, with the exception 
 26 
 
of the alternate-type macrophage and pathogen equations, and additional scaled parameters used 
in the type-I macrophage and cytokine equation.  
 
1
)*1(
1
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cp
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





     (6) 








 1
)1)(1)(1(
1*
*1*
abfcacp
m
cpmp
d
dcp 


  (7) 
( )
1 2
(1 2* )
ut
ab
ca fdma
ma
d ca f

 

  
 
   (8) 
camacp
d
dca
*** 

      (9) 
 )*1(*)1(** macmmp
d
dp
 

   (10) 
 
Table 5:  Non-dimensionalized parameters 
Scaled Parameter Equivalent from Table 4 Value 
  
2*1
1
ks
r
 0.6 - 1.2 
  
2
1
k
k
 1 
  
m
c


 10 
  
mc
sa
 *
1*
 0.5 - 4 
abf  4*kfa  0 – 1.5 
2  
3*2
2
ks
r
 0.4 – 1 
2  
3
1
k
k
 1 
utf  fak
r
r
*3
2
3
 0 - 1 
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  
2
*2
3*2*
m
ca
k
ksp

 0.8 - 2 
  2
1*
m
p se

 20 - 50 
  
1*
*
se
kpg
p
m  0.01 - 2 
  
2
*
1**2*
mp
cp
e
spkdam

 0.5 – 2 
 
The non-dimensionalization process provides a reduction in the total number of variables present 
in the equations.  This allows for a more straightforward analysis of the system.  
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CHAPTER 5:  MATHEMATICAL ANALYSIS 
 
3-VARIABLE MODEL STEADY STATES IN THE ABSENCE OF DIETARY FATTY ACID 
The model was first simplified to analyze the effect of the damage term,  , in a low or absent 
fatty acid diet.  In the absence of a regular supply of dietary fatty acids, the terms abf and utf are 
set to zero.  A steady state analysis is outlined below to determine the value of variables over 
time.  By setting derivatives to zero, the variables are no longer changing.    
The steady state value for anti-inflammatory cytokines is then: 

 macp
ca
**
 .   
Using this to solve for alternative-type macrophages at steady state, we have:   
)22*2(**2
1
 

cp
ma . 
The non-dimensional parameter 2 is a ratio of the saturation constants, can be taken to be close 
to 1.  If 2 is taken to be close to 1, the sum of the terms )22*2(**2  cp is positive and 
leads to a population of ma that is less than 1, that continues to decline as cp grows.  Therefore, 
although the anti-inflammatory cytokines may continue to persist if cp is high, ultimately the 
system reduces to the 3-equation model: 
1
)*1(
1
1
m
cp
cp
d
dm






   (11) 

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
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  (12) 
 1*)1(** mmp
d
dp


   (13) 
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Solving for the steady states, we find that: 
)*1(
*11
cp
cp
m



  
*
* 1
(1 * )* 1
*( 1 )
1
(1 * )
cp
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

 
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 
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
 

 
After substituting in the values of m1 and p above, the steady state for the cp equation is the roots 
of the equation below: 
2 2 4
2 2 2 2 2 2 2 3
2 2 2
( )
( 2 2 2 )
( 2 2 2 2 2 2 2 )
( 2 2 ) 0
cp
cp
cp
cp
   
              
            
       
   
             
             
       
 
Because of the complexity of the cp equation, above, it helps to start by trying to put bounds on 
some of the parameters. First, it is helpful to note that to be biologically relevant, all the 
parameters and variables here are greater than or equal to zero.  With this restriction, any initial 
condition will result in the type-I macrophage equation with 11m .  In the pathogen equation, 
the parameter   is the ratio of bacterial growth to macrophage kill rate.  Larger values indicate a 
more aggressive, quickly growing pathogen that is unmanageable to the type-I macrophage 
population.  It determines bacterial sensitivity, and controls whether an infection can be cleared 
or will become chronic.  The parameter   is a ratio of the damage produced by the different 
types of macrophages.  In order to solve for a steady state value of p greater than or equal to 
zero, we must have  < 1m .   
By substituting in the values of m1 and p into the cytokine equation (12), we have: 
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The parameter  is the ratio of cytokine death rate to macrophage death rates and was taken to 
be .10   After some rearrangement, we have: 
 
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Note that the term on the right of this equation is negative if 1 and .2)1(    Using this, 
we can put bounds on cp by setting .
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Since   includes a multiplier of 
2
1
m
, then .1   In order to maintain a value of ,0cp then 
the term on the left must be positive and greater than or equal: 
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1*1 cp  is positive.   
 31 
 
From the denominator we determine that cp > 
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Varying the parameter   was found to have significant impact on the model.  Since   
determines bacterial sensitivity it will ultimately determine whether an infection is cleared or 
becomes chronic; a low value of   signifies a weaker, non-aggressive pathogen, and a high 
value of   signifies an aggressive, resistant pathogen.  The following parameter values were 
chosen to study the states that occur when varying :   1, 2, 1, 10, 1, 30.            
While the first three of these parameters may change depending on the conditions of the system, 
the last three represent basic biological functions.  To simplify the analysis, these values are 
taken to be constant and 10, 1, 30      will be used for the remainder of this analysis.   
By varying values of  in the three-equation model above, the following changes in stability 
were found using Maple.  The eigenvalues for the system were computed with the different 
parameter values and were analyzed for stability criteria. 
 
 
 32 
 
Table 6:  Steady States for the 3-Variable Model in the Absence of Fatty Acids 
Values of   Eigenvalues 
Stable Fixed Point  
(m1, cp, p) 
  Low:  0.01 <   < 0.5 All negative real part Stable, (1.73, 2.71, 1.06) at   = 0.1 
Medium:  0.5 <   < 1.5 All negative real part Stable, (1.76, 3.25, 3.12) at   = 1.2 
High:  1.5 <  < 2.0 All negative real part Stable, (1.88, 7.58, 22.57) at   = 1.8 
  2 None No fixed points 
 
 The general trend found in the analysis is that as   increases, the steady state values for m1, cp, 
and p all also increase.  However, as   is increased towards a value of 2, m1 maxes out near a 
value just less than 2, while cp and p will increase towards infinity.  If   2, there is no 
equilibrium solution and cp and p will grow unbounded.  
Simulations in XPP with parameter values 0.1, 1, 2, 1, 10, 1, 30             and 
initial conditions ( 1, , ) (1,0,0)m cp p   will result in the fixed point (1.73, 2.71, 1.06) found for 
0.1   in Table 6.  A time scale of hours is used in each simulation.  Thus, the fixed point for 
0.1  is reached within 12 hours.  Pathogen levels reach the steady state value of 1.06 within 1 
hour in the simulation below. 
Figure 6:  Steady States for the 3-Variable System in the Absence of Fatty Acids with 
0.1   reaches steady state at (1.73, 2.71, 1.06). 
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By increasing , the state of chronic inflammation also increases.  The following simulation uses 
  = 1.8, and uses an initial condition of the last fixed point ( 1, , ) (1.73,2.71,1.06).m cp p    The 
solution is now drawn towards the new fixed point of (1.88, 7.58, 22.57) shown in Table 6.  
Notice the spike in pathogens and inflammatory cytokines that is managed by the type-I 
macrophage, but does not return to previous lower fixed points.  This is to be expected from such 
an aggressively growing and resistant strain of pathogen given with   = 1.8.  The fixed point 
contains higher steady state values of type-I macrophage, pro-inflammatory cytokine and 
pathogen. 
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Figure 7:  Steady States for the 3-Variable System in the Absence of Fatty Acids with 
1.8   reaches steady state at (1.88, 7.58, 22.57). 
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Simulations run with the damage function ( 1 ) ( * 1) (0)fd if M c then dam M else  , where 
dam   will result in the same fixed points found above, given an initial condition for m1 > c.   
This leads us to the conclusion that the model has different states of chronic inflammation.  We 
can define these as the “Health” state, which is characterized by low type-I macrophage, low 
pathogen and inflammatory cytokine and occurs with a low damage /   value; a “Low Chronic” 
state which is characterized by low but persistent levels of type-I macrophage which causes 
damage and thereby supporting a positive pathogen population; and a “High Chronic” which is 
characterized by higher levels of type-I macrophage, and very high levels of inflammatory 
cytokine and pathogen.  Figure 6 above shows a “Low Chronic” state, and Figure 7 demonstrates 
a “High Chronic.”  Model health states that occur in the presence and absence of fatty acids are 
further explained in Chapter 6, Results. 
BIFURCATION ANALYSIS 
A bifurcation is any major qualitative change in the dynamical behavior of a system in response 
to a parameter value.  The figure below shows how p increases in response to increasing values 
of  .  
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Figure 8:  Bifurcation diagram - p increases in response to increases in  . 
 
In Herald’s (2009) paper, a bacterial state only occurs where the bacterial population can 
withstand the immune response (  > 1).  However, in this study the damage / leakage term will 
always produce a state with some level of pathogen present with 0.   
Biologically, the change in fixed points in response to   represent the low and high chronic 
states of chronic inflammation mentioned earlier.  In the “low” state,   < 0.5 and the immune 
response is able to manage the pathogen in the system and minimize damage that occurs from 
higher levels of m1.  The “low” state is shown by fixed point #1 in Figure 8.  In the “high” 
inflamed state for   > 1.5, the immune system has much more cp circulating, producing more 
m1, resulting in damage and pathogens leaking in.  This is represented by the region of fixed 
points 2 – 5 in Figure 8.  A bifurcation diagram of type-I macrophage m1 responding to 
increasing values of   has very similar dynamics in which low and high chronic states are 
represented. 
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3-VARIABLE REDUCED MODEL IN THE ABSENCE OF DAMAGE 
Next, it is important to analyze the system when the damage term,  , is small.  If  =0, this 
would effectively reduce the three-equation system to the one studied by Herald (2009).  Four 
equilibrium states were found in Herald’s (2009) analysis:  One healthy state, two inflamed 
states in the absence of pathogens (one high, one low state), and one chronically infected state.  
Whenever  > 0, though, there will always be some pathogen present, and the only likely states 
are the high and low chronic state found earlier.  Therefore, a function was used to study the 
effect of   in simulations.  Ultimately, we are most interested in how the addition of fatty acids, 
and modifying the anti-inflammatory response of the system, will minimize the damage caused 
by m1 cells and the resulting pathogens that leak in. 
There are some interesting changes in stability when  =0.  Since p is zero at steady state, 
varying   no longer has any effect on the fixed points.  However, given the set of parameters 
0.1, 0, 2, 1, 10, 1, 30             , there are 2 fixed points.  The fixed point (1, 0, 0) 
is unstable, and the fixed point (1.71, 2.41, 0) is stable.  The system produces a third unstable 
fixed point at (0.31,-0.41,0), but this is not biologically relevant. 
 
5-VARIABLE MODEL STEADY STATES 
5-VARIABLE MODEL STEADY STATES IN THE ABSENCE OF FATTY ACIDS 
Next, the entire five-equation non-dimensional system was analyzed, with the fatty acid input set 
to zero.  This models a diet low or absent in fatty acids: 
1
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The following parameter values were chosen to study the states that occur when varying :   
1, 2, 1, 10, 1, 30, 2 1, 2 0.75, 1.2, 0.8.c                   The first 6 parameters 
are the same as those used in the previous analysis.  The table below shows the new five-
equation system dynamics.  The “Low” state can be described as a mild flare up in a Crohn’s 
patient, while the “High” state would refer to a major flare up that may require hospitalization 
for a Crohn’s patient. 
Table 7:  Steady States for the 5-Variable Model in the Absence of Fatty Acids 
Values of   Eigenvalues 
Stable point 
(M1,MA,CP,CA,P) 
Low:  0 <   < 0.5 All negative real part 
Stable, (1.64, 1.15,1.76, 
0.24, 0.47) at   = 0.1 
Medium:  0.5 <   < 1.5 All negative real part 
Stable, (1.67, 1.16, 2, 0.28, 
1.58) at   = 1.2 
High:  1.5 <   < 2.0 All negative real part 
Stable, (1.84, 1.34, 5.23, 
0.84, 19.34) at   = 1.8 
  2 None No fixed points 
 
Note that in the absence of fatty acids, the anti-inflammatory cytokine population is much less 
than the pro-inflammatory cytokine population. 
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5-VARIABLE MODEL STEADY STATES IN THE PRESENCE OF FATTY ACIDS 
Adding fatty acids to the system ( 1, 0.8ab utf f  ) produces the following changes: 
Table 8:  Steady States for the 5-Variable Model in the Presence of Fatty Acids 
Values of   Eigenvalues 
Stability 
(M1,MA,CP,CA,P) 
Low:    = 0.1 
2 Fixed Points:  Negative and 
positive; all negative 
Unstable, (1.05, 1.3, 0.05, 
0.01, 0); Stable, (1.18, 1.3, 
0.23, 0.04, 0.13)  
Medium:    = 1.2 
2 Fixed Points:  Negative and 
positive; all negative 
Unstable, (1.04, 1.3, 0.04, 
0, 0); Stable, (1.44, 1.33, 
0.79, 0.13, 1.57) 
High:    = 1.8 
2 Fixed Points:  Negative and 
positive; all negative 
Unstable, (1.04, 1.3, 0.04, 
0.01, 0); Stable, (1.83, 1.43, 
4.91, 0.84, 22.29) 
  2 Negative and positive 
Unstable, (1.04, 1.3, 0.04, 
0.01, 0) at   = 2 
 
Notice that there is a significant suppressed immune response (lower m1, cp values) and 
decreased pathogen population when fatty acids are added to the system at the lowest value of  .  
As   increases, however, any protective effect fatty acids may provide the system from 
pathogens diminishes and total pathogen population rises slightly.  Since   represents the 
pathogen growth rate and resistance to the immune response, this is to be expected.  Low levels 
of   represent a non-aggressive pathogen or antigen that has leaked into the system, possibly of 
the variety normally found in the gut.  The fatty acids help to protect the system by suppressing a 
chronic inflammatory response.  If an aggressive variety of pathogen leaked in, the suppressive 
effect of the fatty acids could be counter-productive.  However, the presence of fatty acids in the 
system does help the model manage values of   2.  The model will not blow up as it would for 
  2 and no fatty acids included in the system.  This analysis indicates that fatty acids would be 
 40 
 
most beneficial to a Crohn’s patient if added regularly to the diet before an inflammatory 
episode, or during a low-chronic state.  If a patient were to add fatty acids during a high chronic 
inflammation state, it could be more detrimental than helpful.  These scenarios will be further 
reviewed in Chapter 6:  Results. 
 
BIFURCATION ANALYSIS 
The 5-variable model with fatty acids included shows the most interesting dynamics.  Based on 
the results shown in Table 8, a bifurcation occurs with the addition of ( 1, 0.8ab utf f  ).  The 
addition of the fatty acid produces a change in both number of fixed points and stability at 
different values of  .  The unstable fixed points have a much lower population of inflammatory 
markers and pathogen.   
The bifurcation diagrams below start from the fixed point at (1.44, 1.33, 0.79, 0.13, 1.57) with   
= 1.2 and fatty acids included.  The following shows p population changing with parameter fab 
(fatty acid absorption).  Based on the figure, the value of fab = 1 gives a stable steady state with 
the best possible (low) value of pathogen.  Earlier analysis has shown that in the absence of fatty 
acids ( 0, 0ab utf f  ) a higher inflamed state will occur.   
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Figure 9:  Bifurcation diagram - p increases in response to increase in fab . 
 
Although an increase in fatty acid absorption parameter does not help to decrease the pathogen 
population, it appears that the fatty acid utilization parameter (fut) will.  Figure 10 below shows a 
saddle node bifurcation of p with changing fut.  Increasing fut to a value of 1.473 will result in a 
lower total pathogen population of 0.51 (point #2 in the diagram.)  Points #3 and #4 are not 
biologically relevant since they have slightly negative values of p.  For values of fut less than 
1.473, stable fixed points occur for p > 0 and unstable fixed points occur where p < 0.  There are 
no fixed points for values of fut > 1.473. 
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Figure 10:  Bifurcation diagram – p decreases in response to increase in fut . 
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CHAPTER 6:  RESULTS 
 
THE NORMAL HEALTH STATE AND THE LOW CHRONIC STATE 
The normal Health State is characterized by a resolved infection; pathogens are driven to zero or 
near zero; anti-inflammatory markers m1 and cp have reduced levels that do not cause damage.  
The Health State can be achieved when the damage parameter 0.    This will occur when type-
I macrophages are at a normal threshold that does not cause damage.   
 
PATHOGENS ARE INTRODUCED IN A HIGH FATTY ACID DIET 
The following simulations show an infection returning to the Health State (m1, ma, cp, ca, p) = 
(1.12, 1.3, 0.25, 0.04, 0.16) with initial conditions (m1, ma, cp, ca, p) = (1, 1, 0, 0, 0.5).  Fatty 
acids have been included in this model.  The oscillations seen are due to m1’s response to the 
spike in p, and the fatty acid / anti-inflammatory effect dampening this response.  These two 
forces oscillation back and forth until an equilibrium is reached. The pathogens are initially seen 
to spike in population, but within 72 hours (3 days) the infection has been cleared, and 
inflammatory cells return to normal levels.  The threshold at which damage will occur has been 
set to m1 = 1.4, using the damage function fd described in earlier sections. 
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Figure 11:  Pathogens introduced in a high fatty acid diet 
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Type I macrophages and combined alternate type macrophages will return to steady-state 
background levels of 1.  The background levels allow the body to quickly mount an immune 
response if pathogens are introduced to the system.  Cytokines return to a near - zero steady 
state, since epithelial cells, mast cells, and macrophages are not reacting to a pathogen stimuli. 
The presence of fatty acids in the system encourages a higher alternate macrophage steady state.   
PATHOGENS ARE INTRODUCED IN A LOW FATTY ACID DIET 
A low, or no fatty acid diet will produce a higher type-I macrophage steady state.  The same 
simulation is run with fatty acids set to zero.  The higher type-I macrophage steady state triggers 
damage and increases pathogen population.  Within 24 hours, this has resulted in a low chronic 
state with steady state (m1, ma, cp, ca, p) = (1.67, 1.16, 2, 0.28, 1.58.)  
Figure 12:  Pathogens introduced in a low fatty acid diet 
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Re-starting the simulation with the ending chronic infection state as the new initial conditions but 
now with fatty acids added back in was able to force the steady states back to normal levels.  
Note:  A higher value of fut was required ( 1, 1.45)fab fut   than if fatty acid was included 
initially at ( 1, 0.8)fab fut  . 
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Figure 13:  Introducing fatty acids during a low-chronic state 
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THE HIGH CHRONIC STATE 
 
EFFECTS OF A ADDING A HIGH FATTY ACID DIET 
The simulations above show the health state, and a low chronic state that occurs in the absence of 
fatty acids in the diet.  The next set of simulations starts with a high chronic state and introduces 
the same fatty acid diet combo   ( 1, 1.45)fab fut  that was able to resolve the low chronic 
state.  The high chronic steady state was found with fatty acid set to zero, and then added again  
for the initial conditions:  ( m1, ma, cp, ca, p ) = ( 1.84, 1.34, 5.23, 0.84, 19.34 ). 
Although the addition of fatty acids does lower the type-I macrophage population, pathogen 
levels do not respond as before.  In this case, adding fatty acids at such a high chronic state 
would be more detrimental to a patient than beneficial because it dampens the inflammatory 
process which allows the infection to gain an even stronger foothold. 
 
Figure 14:  Introducing fatty acids during a high-chronic state 
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These results indicate that 1) fatty acids regularly added to the diet will help protect an individual 
prone to intestinal inflammation from entering into a low chronic state and stay within a health 
state; and 2) fatty acids added regularly to the diet of an individual already within a low chronic 
state return to a health state.  Finally, adding fatty acids to the diet of an individual already in a 
high chronic state is not advised.  Adding fatty acids could be detrimental to the immune 
response fighting a high pathogen population.  If antibiotics or medications were to lower the 
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high chronic state to a lower chronic state, then fatty acids could safely be added to bring the 
individual back to a health state. 
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CHAPTER 7:  CONCLUSIONS 
 
Type-1 macrophages are activated from undifferentiated macrophages by TNF and also secrete 
TNF (Mosser, 2003.)  The punicic acid murine trial performed by Bassaganya-Riera (2011) 
shows that when mice are fed a diet high in punicic acid, values for TNF are significantly 
different than levels found in control mice, and monocyte chemoattractant protein shows 
diminished values compared to control, although not found to be statistically significant.  Thus, 
in modeling the effects of a specific fatty acid diet fed to patients of IBD or Crohn’s, we would 
expect to see a lower recruitment of macrophages, a lower level of type-1 macrophages, and 
lower levels of pro-inflammatory cytokines produced by the type-1 macrophages, since all these 
processes are repressed by the activated PPAR receptor in the presence of appropriate fatty acid 
ligands.  Further, as shown in the murine study by Bassaganya-Riera, the diminished levels of 
type-I macrophages leads to a lowered incidence of sores and intestinal damage.  Therefore, 
although the total type-I macrophage population is suppressed and leads to a slower kill rate of 
pathogens, the resulting decrease or lower incidence of intestinal tissue damage ensures that 
fewer pathogens will infiltrate damaged tissues from the intestinal lumen.  Also, chronic 
inflammation is unlikely to occur in this scenario as pathogens are slowly but methodically 
removed and the inflammatory response is controlled. 
Many models of inflammation have been presented in the literature, but few have included the 
anti-inflammatory effects of alternate-type macrophages and the dynamics that control their 
levels in the system.  Several studies have documented the anti-inflammatory effects of PPAR-
gamma on Monocytes and macrophages (Ricote et al., 1998), (Jiang et. al., 1998) and found 
significant amounts of the PPAR-gamma receptor on Neutrophils, T lymphocytes, B 
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lymphocytes, NK cells, Dendritic cells, Eosinophils and mast cells (Sugiyama et al., 2000), 
(Szeles et al., 2007).  It may be that anti-inflammatory cytokine / ligand population dynamics are 
just as important to the system (and health of the individual) as the pro-inflammatory cytokines 
(which perpetuate chronic inflammation.) 
The 5-variable model developed in this study included the dynamics of fatty acids on PPAR 
receptors of inflammatory cells and was able to simulate the results described in the studies by 
Bassaganya-Riera and Ricote.  Simulations demonstrated that fatty acids included regularly in 
the diet will help protect an individual from entering into a chronically inflamed state, and will 
help an individual already in a low chronically inflamed state return to a health state.  However, 
results indicated that fatty acids should not be added to the diet of an individual already in a high 
chronic inflamed state, as this would be detrimental to the immune response in place. 
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CHAPTER 8:  OPEN QUESTIONS AND DISCUSSION 
 
Each model gives a part of the puzzle, but none give a full picture.  In the context of studying the 
anti-inflammatory effects of PPAR-gamma, it may be prudent to track ongoing undifferentiated 
and differentiated macrophage populations since studies have documented the anti-inflammatory 
effects of PPAR-gamma on monocytes and macrophages (Ricote et al., 1998), (Jiang et. al., 
1998) and found significant amounts of the PPAR-gamma receptor on neutrophils, T 
lymphocytes, B lymphocytes, NK cells, dendritic cells, eosinophils and mast cells (Sugiyama et 
al., 2000), (Szeles et al., 2007). 
In light of the fact that none of the models presented earlier specifically make any allocation for 
the dynamics of the PPAR-gamma receptor in the equations for mast, monocyte, macrophage 
cells, it would be interesting to include this dynamic, most likely at the point of differentiation 
(and population growth) of these cells, and see if the results found by each model would be the 
same.  If the PPAR-gamma receptor activity is tracked, then an anti-inflammatory cytokine and 
possibly a separate variable for up-regulating ligands specific to PPAR-gamma should also be 
tracked.  It may be that anti-inflammatory cytokine / ligand population dynamics will be found to 
be more important to the system (and health of the individual) then the pro-inflammatory 
cytokines (which perpetuate chronic inflammation.) 
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APPENDICES 
 
XPP CODE for 3-Variable System: 
 
par alpha=1 
par Beta=1 
par delta=10 
par phi=2 
par k=30 
par O=0.1 
par gamma=1 
 
% par c=1 
% par dam=0.1 
 
dM1/dt=1+(alpha*CP/(1+Beta*CP))-M1 
dCP/dt=P*M1+delta*CP*((phi*M1/(1+CP))-1) 
dP/dt=k*(P*(O-M1)+gamma*m1) 
% gamma=if(M1>c)then(dam)else(0) 
% c corresponds to the percentage difference that will give damage. 
@ total=48, dt=0.01, xhi=100, bound=100000 
Done 
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XPP CODE for 5-Variable System: 
 
par alpha=1 
par alpha2=0.75 
par Beta=1 
par Beta2=1 
par s2=1 
par fut=0.8 
par fab=1 
par delta=10 
par phi=2 
par S=1.2 
par k=30 
par O=1.2 
par c=0.8 
par dam=1 
par a=1.2 
 
 
dM1/dt=1+(alpha*CP/(1+Beta*CP))-M1 
dMA/dt=s2+(alpha2*(CA+fut)/(1+Beta2*CA+fab))-MA 
dCP/dt=P*M1+delta*CP*((phi*M1/((1+CP)*(1+CA)*(1+fab)))-1) 
dCA/dt=S*CP*MA-delta*ca 
dP/dt=k*(P*(O-M1)+gamma*(m1-c*ma)) 
gamma=if(M1>a)then(dam)else(0) 
% c corresponds to the percentage difference that will give damage. 
@ total=30, dt=0.01, xhi=100, bound=100000 
Done 
